Pemigatinib price from Innovent

Pemigatinib (Pemigatinib) The original drug has been approved by the State Food and Drug Administration for marketing. Currently, there is no domestic drug of Pemigatinib produced by Innovent Biopharmaceuticals on the market in China. Pemetinib has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma who have fibroblast growth factor receptor 2 (FGFR2) fusions or rearrangements and have progressed after at least one systemic therapy.

This means it will be suitable for patients with cholangiocarcinoma who have been tested for an abnormal genetic change in their tumors called FGFR2 fusions or rearrangements, a defect that can lead to cancer growth. It is estimated that about 15% of patients diagnosed with cholangiocarcinoma have this defect. Pemetinib was developed by the American company Incyte. It is a kinase inhibitor drug that works by blocking the abnormal FGFR2 protein in bile duct tumor cells and preventing cell growth.

The original drug Pemetinib has been on the domestic market for a short time, so it has not yet entered the scope of medical insurance. The price of each box of 9mg*14 tablets may be around 50,000 yuan, which is expensive. The original drug Pemetinib currently on the market overseas, with a specification of 13.5mg*14 tablets, may cost around RMB 70,000 per box (the price may fluctuate due to exchange rates). There are also generic pemetinib drugs produced in other countries overseas, and their drug ingredients are basically the same as those of the original drugs sold abroad. For example, the price of 4.5mg*14 tablets per box produced by a Laos pharmaceutical factory may be around 1,000 yuan (the price may fluctuate due to exchange rates).